

# Oklahoma Health Care Authority

## Drug Utilization Review Board

### (DUR Board)

Meeting – February 14, 2024 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:**     ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

### **AGENDA**

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

#### **1. Call to Order**

A. Roll Call – Dr. Wilcox

#### **DUR Board Members:**

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person
Dr. Cindy West –	participating in person

#### **Viewing Access Only via Zoom:**

Please register for the meeting at:

[https://oklahoma.zoom.us/webinar/register/WN\\_R\\_AmCBepQpGQggKXT40uxg](https://oklahoma.zoom.us/webinar/register/WN_R_AmCBepQpGQggKXT40uxg)

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 919 6475 4191

Passcode: 95646190

## **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. December 13, 2023 DUR Board Meeting Minutes
- B. December 13, 2023 DUR Board Recommendations Memorandum
- C. January 10, 2024 DUR Board Recommendations Memorandum

Items to be presented by Dr. Moss, Dr. O'Halloran, Dr. Muchmore, Chairman:

### **4. Update on Medication Coverage Authorization Unit/Use of Glucagon-Like Peptide-1 (GLP-1) Agonists and Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors with Cardiovascular (CV) Benefit in Members with Type 2 Diabetes (T2D) and High CV Risk or Established Atherosclerotic CV Disease (ASCVD) Mailing Update – See Appendix B**

- A. Pharmacy Help Desk Activity for January 2024
- B. Medication Coverage Activity for January 2024
- C. Use of GLP-1 Agonists and SGLT-2 Inhibitors with CV Benefit in Members with T2D and High CV Risk or Established ASCVD Mailing Update

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

### **5. Action Item – Narrow Therapeutic Index (NTI) List – See Appendix C**

- A. Introduction
- B. NTI List
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Rystiggo® (Rozanolixizumab-noli), Vyvgart® Hytrulo (Efgartigimod Alfa/Hyaluronidase-qvfc), and Zilbrysq® (Zilucoplan) and Update the Approval Criteria for the Complement Inhibitors and Miscellaneous Immunomodulatory Agents – See Appendix D**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Exxua™ (Gepirone) and Zurzuvae™ (Zuranolone) and Update the Approval Criteria for the Antidepressants – See Appendix E**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Elfabrio® (Pegunigalsidase Alfa-iwxj), Opfolda™ (Miglustat), and Pombiliti™ (Cipaglucosidase Alfa-atga) and Update the Approval Criteria for the Lysosomal Storage Disease Medications – See Appendix F**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Daugherty, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Hepzato Kit™ (Mephalan) and Zynyz™ (Retifanlimab-dlwr) and Update the Approval Criteria for the Skin Cancer Medications – See Appendix G**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Daugherty, Dr. Muchmore, Chairman:

**10. Action Item – Vote to Update the Approval Criteria for the Gastrointestinal (GI) Cancer Medications – See Appendix H**

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Daugherty, Dr. Muchmore, Chairman:

**11. Action Item – Vote to Prior Authorize Iwilfin™ (Eflornithine), Kepivance® (Palifermin), Loqtorzi™ (Toripalimab-tpzi), and Omisirge® (Omidubicel- only) – See Appendix I**

- A. Market News and Updates

- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Daugherty, Dr. Muchmore, Chairman:

**12. Action Item – Vote to Prior Authorize Ogsiveo™ (Nirogacestat) – See Appendix J**

- A. Ogsiveo™ (Nirogacestat) Product Summary
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**13. Action Item – Vote to Prior Authorize Xphozah® (Tenapanor) and Update the Approval Criteria for the Hyperphosphatemia Medications – See Appendix K**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**14. Action Item – Vote to Prior Authorize Atorvaliq® (Atorvastatin Oral Suspension) and Update the Approval Criteria for the Antihyperlipidemics – See Appendix L**

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

**15. Action Item – Vote to Prior Authorize Oxybutynin 2.5mg Tablet and Update the Approval Criteria for the Bladder Control Medications – See Appendix M**

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**16. Action Item – Vote to Prior Authorize iDose® TR (Travoprost Intracameral Implant) and Update the Approval Criteria for the Glaucoma Medications – See Appendix N**

- A. Market News and Updates
- B. iDose® TR (Travoprost Intracameral Implant) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**17. Action Item – Annual Review of Otic Anti-Infective Medications – See Appendix O**

- A. Current Prior Authorization Criteria
- B. Utilization of Otic Anti-Infective Medications
- C. Prior Authorization of Otic Anti-Infective Medications

- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Otic Anti-Infective Medications

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

**18. Action Item – Annual Review of Topical Acne, Psoriasis, and Rosacea Products – See Appendix P**

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Acne, Psoriasis, and Rosacea Products
- C. Prior Authorization of Topical Acne, Psoriasis, and Rosacea Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Topical Acne, Psoriasis, and Rosacea Products

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**19. Action Item – Annual Review of Antiviral Medications – See Appendix Q**

- A. Current Prior Authorization Criteria
- B. Utilization of Antiviral Medications
- C. Prior Authorization of Antiviral Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Antiviral Medications

Items to be presented by Dr. Daugherty, Dr. Muchmore, Chairman:

**20. Annual Review of Leukemia Medications and 30-Day Notice to Prior Authorize Vanflyta® (Quizartinib) – See Appendix R**

- A. Current Prior Authorization Criteria
- B. Utilization of Leukemia Medications
- C. Prior Authorization of Leukemia Medications
- D. Market News and Updates
- E. Vanflyta® (Quizartinib) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Leukemia Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**21. Annual Review of Anti-Migraine Medications and 30-Day Notice to Prior Authorize RizaFilm® (Rizatriptan Film) and Zavzpret™ (Zavegepant Nasal Spray) – See Appendix S**

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Migraine Medications
- C. Prior Authorization of Anti-Migraine Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Migraine Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**22. Annual Review of Anti-Parasitic Medications and 30-Day Notice to Prior Authorize Xdemvy™ (Lotilaner Ophthalmic Solution) – See Appendix T**

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Parasitic Medications
- C. Prior Authorization of Anti-Parasitic Medications
- D. Market News and Updates
- E. Xdemvy™ (Lotilaner Ophthalmic Solution) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Parasitic Medications

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

**23. 30-Day Notice to Prior Authorize Ycanth™ (Cantharidin) and Zelsuvmi™ (Berdazimer) – See Appendix U**

- A. Introduction
- B. Market News and Updates
- C. Product Summaries
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**24. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix V**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**25. Future Business\* (Upcoming Product and Class Reviews)**

- A. Hemophilia Medications
- B. Growth Hormone Products and Voxzogo® (Vosoritide)
- C. Lymphoma Medications
- D. Multiple Sclerosis (MS) Medications

\*Future product and class reviews subject to change.

**26. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.